Breaking News

Nestle Expands Skin Health Platform

May 28, 2014

To purchase key assets of Valeant Pharmaceutical for $1.4 billion.

Looks like Nestlé is serious about skin health. Today, the company said it will reinforce its newly-created Nestlé Skin Health unit with the the full rights to commercialize several key aesthetic dermatology products from Valeant Pharmaceuticals International. The $1.4 billion cash deal is for the US and Canada. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercialises the products included in this transaction outside those markets, according to Nestlé.

Under terms of the agreement, Nestlé is acquiring the full rights to commercialise in the US and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the US, Canada and many markets around the world.

“With this deal we have acquired key strategic assets to extend Nestlé’s activities in the field of specialised, medical skin treatments, providing consumers with life-enhancing scientific products,” said Nestlé Chairman Peter Brabeck-Letmathe.

“This move will reinforce Galderma’s leading position in the industry when it becomes Nestlé Skin Health by allowing it to complete its geographic footprint for its strong portfolio of brands and leading medical solutions globally,” said Nestlé Chief Executive Paul Bulcke.

The transaction is subject to regulatory approval and customary closing conditions.

Back in February,  Nestlé announced it would extend its activities to include the field of specialized medical skin treatments through the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a broad range of innovative and scientifically-proven products. The foundation for the company would be Galderma, the 50/50 joint venture with L’Oréal, which would become fully-owned by Nestlé. Bübchen, Nestlé's existing infant skin care business, would be merged into the new entity.

The acquisition of Galderma is awaiting final regulatory clearance.

 

Related End-User Markets:

Related Raw Materials:

  • Erasa

    Erasa's New Evangelist(a)

    January 9, 2017
    Impressed by the performance of its hero SKU, supermodel Linda Evangelista joins the company in a hand's on role.

  • Discourse on Disclosure

    Discourse on Disclosure

    Tom Branna, Editorial Director||January 6, 2017
    Transparency impacts the cleaning industry.

  • The Top Stories of 2016

    The Top Stories of 2016

    December 26, 2016
    The companies and topics that grabbed headlines and your attention this year.

  • Hitting the Right Notes

    Hitting the Right Notes

    January 6, 2017
    Agilex Fragrances is the leader in the middle market fragrance category.

  • The Smell of Clean in 2017

    The Smell of Clean in 2017

    January 6, 2017
    Changing consumer lifestyles and demographics are impacting the scents found in the household cleaning category.

  • On the Edge

    On the Edge

    January 6, 2017
    Expanding beauty brands to watch in 2017